Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

Recent advancements in therapy and pharmacological treatments are significantly boosting the aHUS market. The development of new complement inhibitors, specifically the C5 inhibitors eculizumab and ravulizumab, has dramatically improved patient outcomes by mitigating complications from thrombotic microangiopathy. Ongoing research on modulating immune responses using small molecule inhibitors, monoclonal antibodies, and gene therapy is expected to yield even better long-term treatment options. The introduction of biosimilars is also improving access and affordability. The market is expanding, driven by a growing number of clinical trials for next-generation complement inhibitors. Furthermore, advancements in diagnostic procedures have increased detection rates, enhancing the demand for advanced therapies. Regulatory approvals and indications extensions for existing drugs are also supporting market growth.

Collaboration between biopharma companies and research institutions is accelerating innovations, making this a dynamic and rapidly evolving treatment landscape. Recent examples of collaboration and approvals include:

Examples of Key Developments

In January 2025, Samsung Bioepis and Teva Pharmaceutical partnered for licensing, development, and commercialization of EPYSQLI (eculizumab-aagh), a biosimilar of Soliris (eculizumab) in the U.S. Under the agreement, Samsung Bioepis will handle development, regulatory approvals, manufacturing, and supply, while Teva will oversee commercialization. Similarly, in July 2024, EPYSQLI received approval through the Biologics License Application (BLA) from the FDA for aHUS treatment. These developments underscore the robust activity in the aHUS market.

Historic and Modernized Marketed Therapies in aHUS

Soliris (Eculizumab): AstraZeneca Rare Disease

Soliris (Eculizumab) is a monoclonal antibody developed by Alexion, AstraZeneca Rare Disease, and approved for aHUS treatment. It inhibits the complement protein C5, preventing uncontrolled complement activation that leads to hemolysis, thrombotic microangiopathy, and organ damage. By reducing the risk of kidney failure and improving overall disease management, Soliris has been a cornerstone in aHUS treatment.

Ultomiris (Ravulizumab): AstraZeneca Rare Disease

Ultomiris (ravulizumab) is a long-acting C5 complement inhibitor developed by Alexion, AstraZeneca Rare Disease, and approved for aHUS treatment. It prevents uncontrolled complement activation, thereby reducing thrombotic microangiopathy and safeguarding kidney function. Ultomiris offers patients a more convenient treatment regimen with less frequent dosing.

Emerging Therapies in aHUS

Iptacopan: Novartis Pharmaceuticals

Developed by Novartis, Iptacopan is an oral, first-in-class Factor B inhibitor targeting the alternative complement pathway. Ongoing clinical trials are evaluating its efficacy and safety for aHUS, aiming to provide comprehensive control over complement-mediated thrombotic microangiopathy.

NM8074: NovelMed Therapeutics

NM8074 is a humanized anti-Bb monoclonal antibody developed by NovelMed Therapeutics. It selectively inhibits the alternative complement pathway by targeting the Bb protein, treating aHUS without compromising essential immune functions.

Crovalimab: Chugai Pharmaceutical/Roche

Crovalimab is an investigational anti-C5 recycling monoclonal antibody designed to inhibit the complement system by targeting the C5 protein. Its innovative recycling mechanism allows for sustained complement inhibition with low-dose subcutaneous administration every four weeks, potentially reducing the treatment burden for patients.

Regional Analysis

Major markets for aHUS include the U.S., Germany, France, the United Kingdom, Italy, Spain, and Japan. The U.S. has the largest patient pool for aHUS and the biggest market for its treatment. Eculizumab and ravulizumab, complement C5 inhibitors, have significantly improved the standard of care for aHUS. These medicines have led to a marked improvement in kidney function recovery and patient outcomes. Ongoing research focuses on the genetic basis and novel therapeutic approaches in aHUS, paving the way for future advancements.

“Moreover, a genetic mutation has been identified in complement-regulatory proteins like thrombomodulin, which is essential in the development of the disease. Eculizumab and ravulizumab are complement C5 inhibitors that largely manage disease progression while improving outcomes for the patients receiving them. These medicines offer a complete revolution in the management of aHUS…”

Market Challenges and Opportunities

The aHUS market faces both challenges and opportunities. A significant challenge is the high cost of innovative therapies, which can be a barrier for patients without adequate insurance coverage or financial support. However, the growing number of clinical trials and the entry of biosimilars present opportunities to make these treatments more accessible and affordable.

Future Outlook

The future of the aHUS market looks promising, with continued innovation and advancements in treatment options. As research progresses, we can expect to see more targeted therapies with fewer side effects and improved patient outcomes. The collaboration between pharmaceutical companies, research institutions, and regulatory bodies will play a crucial role in driving this progress.

Key Takeaways

• The aHUS market is expected to grow at a CAGR of 4.1% from 2025 to 2035.
• Increasing awareness, improved diagnostics, and novel therapies are driving market growth.
• The U.S. is the largest market for aHUS, with significant contributions from major pharmaceutical companies.
• Emerging therapies and biosimilars are expected to enhance treatment accessibility and affordability.
• Collaboration and regulatory support are critical for continued market growth and innovation.